BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
about
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cellsInjectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)Current and future antiviral therapy of severe seasonal and avian influenzaAssembly of endocytic machinery around individual influenza viruses during viral entry.Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsRecent progress in structure-based anti-influenza drug designNeuraminidase inhibitors for influenza B virus infection: efficacy and resistanceMolecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases.The Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesStructural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesStructural Insights into Substrate Specificity in Variants of N-Acetylneuraminic Acid Lyase Produced by Directed EvolutionInfluenza A Virus N5 Neuraminidase Has an Extended 150-CavityCrystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active siteCrystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6Serendipitous discovery of a potent influenza virus a neuraminidase inhibitorPeramivir injection in the treatment of acute influenza: a review of the literatureInfluenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological ActivityPeramivir (BCX-1812, RWJ-270201): potential new therapy for influenzaInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceRWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenzaNovel alpha- and beta-amino acid inhibitors of influenza virus neuraminidaseCyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activitiesIn vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza virusesComparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivirComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Pandemic influenza: implications for preparation and delivery of critical care servicesTop-hits for H1N1pdm Identified by Virtual Screening Using Ensemble-based DockingEfficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesPlasticity of 150-loop in influenza neuraminidase explored by Hamiltonian replica exchange molecular dynamics simulationsParallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitorsPermeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatmentI222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) virusesLocking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitorsThe N-terminal fragment of a PB2 subunit from the influenza A virus (A/Hong Kong/156/1997 H5N1) effectively inhibits RNP activity and viral replicationExploring the chemical space of influenza neuraminidase inhibitorsEmergence and pandemic potential of swine-origin H1N1 influenza virusDrug resistance in influenza A virus: the epidemiology and management.One-bead-one-inhibitor-one-substrate screening of neuraminidase activity.Conformation and Linkage Studies of Specific Oligosaccharides Related to H1N1, H5N1, and Human Flu for Developing the Second Tamiflu.
P2860
Q24559989-53FE4A3C-5894-4E9A-A8BC-53B15A050361Q24645944-C7EF1E20-EF2A-4200-8F0B-677E3A88700CQ24656164-454A6ED6-E19C-4A60-99F7-9A06BE397F77Q24669815-74809F3C-5049-4EAE-BB6E-291A80E5EB47Q26749578-71B73B6E-035C-4A42-92E4-465809BC5E58Q26863710-E1F92843-BD22-4D68-A4A3-2C1B35642525Q27021579-20230704-EE99-4D96-8EE1-911CF17E9A36Q27334466-64BA4C80-70B3-43FF-864C-E501D9FECB79Q27489856-C41952A3-8286-49C1-905C-35C2EFD52DA1Q27663966-5427B0B1-2BDE-448E-8E17-4B8B575A46F1Q27664358-A6F5F59F-6C38-456D-87FC-749387F812F5Q27666275-08B275EF-AED3-4491-A281-B2662A1CACD4Q27673677-D3AFA95F-86C4-44AA-8D51-52B447E8D2EEQ27678898-FB6FDAB9-DAEE-402F-9FFC-48B67C8D0249Q27687973-E826AAB4-9761-415F-99EA-980B83ED3EC5Q28068310-8E51B751-6390-4600-9BE1-E9A3DECCF54CQ28079041-FEDC6E58-68D9-45CA-92C0-EA037370A4CDQ28201381-DA368A75-60B7-452F-9E0F-715459C82048Q28282405-00159365-A924-4B12-96ED-9ABF9DBC5F07Q28344592-096E7D72-29E9-492E-A7E9-9E51EF8B7F63Q28345965-240A3D4D-BC57-4DC4-B23C-E4CA3654FFC3Q28349496-229963EA-A4A2-4FE8-99B3-AB9405F49C5AQ28349519-B2930262-19FC-4977-83C9-972E49B382DCQ28353147-D5FCBD37-6211-48B1-BD23-8369DEC536D1Q28360732-7FBF2A59-51A1-42F6-81BB-5AAF2D50FC0BQ28364114-45331479-6288-4784-A2E8-BB2B134F6CEAQ28390930-36C224BE-6AF8-4168-9400-773E56D2C4CFQ28471606-D6127B97-AC74-4242-B1CB-33D2A26A2067Q28473051-68DE19F3-0CF5-4867-AE73-C161CB75C16BQ28486130-F245A6F9-B373-4996-86AD-4188A5F3FC9EQ28486252-656AA103-9BD8-4E09-AF52-4F4F84928433Q28486267-FA10E8A3-06DF-49ED-B849-FDE8519E02CFQ28533778-D0A40D30-FE72-4820-BB7C-86A26AAFA264Q28535754-ADD0DB0A-3F72-42EF-AE75-7C2BC3EB913BQ28542440-B787D505-5FA8-4C79-AD48-FF8F58B53650Q28834425-D9CF7737-6505-494A-9EDC-99B8784148BDQ29619003-F6BA6392-86F2-4B2C-A051-691204014AF3Q30234600-23B29C8A-9B60-4F94-855A-54B86CD6073BQ30351369-68D796B8-989A-4133-A44D-AD849618B0F4Q30361636-9951F8EF-8805-4D44-9460-AD67E744FEA5
P2860
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@ast
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@en
type
label
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@ast
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@en
prefLabel
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@ast
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@en
P2093
P356
P1476
BCX-1812 (RWJ-270201): discove ...... h structure-based drug design.
@en
P2093
A Dehghani
A J Elliott
C D Parker
J A Montgomery
S L Ananth
P304
P356
10.1021/JM0002679
P407
P577
2000-09-01T00:00:00Z